Herantis Pharma Featured in the June 2021 Nature Journal
Herantis Pharma Plc, Company release, 2 June 2021 at 9:30 AM EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, announced today that the company was featured in the annual publication of Nature Magazine's BioPharma Dealmakers June 2021 edition which focuses on the latest developments in CNS. The Herantis article, titled, Protecting the proteome from Parkinson’s disease, details how Herantis is capitalizing on the power of the natural protein Cerebral Dopamine Neurotrophic Factor (CDNF) to restore